Last week, we wrote about a new study in the American Journal of Managed Care that determined the addition of a prescription drug program to Medicare expanded access and increased the chances Medicare patients took the medicines prescribed by their doctors. This, in turn, contributed to a savings of $2.3 billion for the Medicare system. This study focused on Medicare beneficiaries who had congestive heart failure, but the same story holds true when you look at an even broader sample.
Future medicines
more
The MODDERN Cures Act
When it comes to treating rare diseases and conditions for which they are few or no existing medicines, improvements can be made to the U.S. regulatory system. The Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network (MODDERN) Cures Act would dramatically transform the drug development and approval process and allow new, safe drugs that treat or cure unmet medical needs to come to market faster.
Access to medicines
more
Medicare Part D
The Medicare prescription drug program, Part D, is the rare government program that is costing less than projected and exceeding expectations. However, Congress is considering proposals that would change Medicare and could mean higher out-of-pocket costs and less choice of medicines for older Americans. Join us in telling Congress to leave Part D alone.
Access to medicines
more
The Patient Protection and Affordable Care Act
Federal health care reform, officially known as the Patient Protection and Affordable Care Act (ACA), was passed into law in 2010 and upheld by the Supreme Court in 2012. The Campaign for Modern Medicine is working alongside advocates across the country to ensure the ACA's implementation brings quality health care to the tens of millions of Americans who currently lack it, and improves the quality of care for those who already have it.
Safe & effective medicines
more
The Prescription Drug User Fee Act
The Prescription Drug User Fee Act (PDUFA) helps the FDA ensure that patients have timely access to breakthrough medicines and that the U.S. continues to be the global leader in delivering these new, lifesaving cures and treatments. During the fifth reauthorization of PDUFA in 2012, we urged legislators to pass a clean and timely PDUFA in order to benefit patients and American innovation.
Improving public health
more
Alzheimer's Disease
Alzheimer's disease can affect anyone. It is one of the most devastating diseases anyone can face. As patients, providers, industry, and caregivers, we must work with policy makers to bring hope to millions of Americans struggling with Alzheimer's.
CMM States
more
Texas
With its large and diverse population, Texas presents a unique opportunity for the Campaign for Modern Medicines to engage in a robust, meaningful and forward-looking discussion to help shape the state's health care debate and deliver better health outcomes for its residents. Therefore, we are launching a campaign within CMM that focuses specifically on the health care challenges Texas faces and how policymakers and advocates can work together to have a real impact on the policy decisions that will improve Texans' health.
MODDERN Cures: Who, What, and Why?
How can we encourage policymakers to support legislation that promotes innovation in research for medicines that treat unmet medical needs? It's a question that the MODDERN Cures Act can help answer.
The History of Part D: Bipartisan Support in 2003
After 38 long years of negotiations between dozens of legislators, through several presidencies, and despite many failed attempts, Congress passed the Medicare prescription drug benefit in 2003. Medicare Part D now offers coverage to more than 31 million American seniors, who report a 90% satisfaction rate with the program, which has also increased medication adherence among older Americans.
